The SCP- ADC™ Platform is an innovative and patented multi-valiant antibody alternative system of multi- indicated Performa. It permits the manufacturing of poly-valiant clinically indicated and proficient of meticulous bridge structures transversely targeted for many malignancies, autoimmune diseases as well as novel indications and effectors. By announcing original expurgated locations and designated structures of protein and polysaccharide cross links within the native immune- globins, Global Allied Pharmaceuticals (GAP) has established an exhilarating multivalent ADC bridging of structure which could bring the improvement of unique mirror image ubiquitous systems and domains to bind specifically and precisely into the landing gears of the targeted tissues. Supplementary benefits of this unique system embraces its lack of distinctive effector commotion, properly controlled immunogenicity and value-added tissue infiltration. Our system based therapeutics also help from the long serum half-life which is at least 5X against the other “scaffolding” systems of ADC’s. The use of this paradigm also delivers the prospect for the production of the vaccines and proteins in infectious disease areas of therapeutics.
 |
| www.gapsos.com |
The system of our framework is a non- antibody specific poly /- diametric antibody arrangement which contains of more than 3 different heavy hawsers and unique light manacles designed to completely accumulate into a single molecule, permitting multi- detailed binding to more than 3 antigens or drug specific targets. This organization delivers the precisely targeted in its class elucidation to the expansion of innovative multi- purpose and specific antibodies based on non- specific antibody arrangement deprived of trusting on substance linkers or chimeric concepts. The grace of this system marks in multi- targeted antibodies without biophysical physiognomies, immunogenicity profiles and CMC feasibility in cost and operations. GAP has industrialized poly diametric paradigm of an ADC by manufacturing proprietary structures unique to the specific antibody class and produce them into covalent boding of a structure with the ability to consistently produce the proper domain to the different classes of antibodies. We range from structure domain analysis of Fc regions of IgGs into other specific regions of MABs. In addition to afford the basis for poly specific, the compensations of the unique systems include well designed effector function, ultimate bioavailability systems, uniquely provided by us at Global Allied Pharmaceuticals (www.gapsos.com).
No comments:
Post a Comment